Immunocore Holdings reported $102.2 million in net revenues for Q3 2026, showing 10% year-over-year growth. The company completed enrollment for its Phase 3 trial in advanced cutaneous melanoma, with survival data expected in Q2 2027. It also presented promising early data for a combination therapy in metastatic uveal melanoma and dosed the first patient in a Phase 1 trial for type 1 diabetes. Immunocore holds $901 million in cash and securities, supporting ongoing research and development.
Immunocore's recent financial results provide context for health-sector market activity on Pluang. For readers following this sector, here is Pluang's market snapshot as of Nov 06, 2026 20:42 WIB: Out of 150 health stocks, 51 advanced while 94 declined. GMED fell sharply by 10.37% to USD 73.07 with a typical hold time of 13 days and exclusively buy-side order activity. In contrast, HIMS rose 8.69% to USD 26.15, held for 23 days on average, with 65% buy orders. GH dropped 7.12% to USD 142.50, held for 9 days.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
